Last reviewed · How we verify
VONVENDI
VONVENDI is a recombinant von Willebrand factor (VWF) that replaces deficient or dysfunctional VWF to restore platelet adhesion and hemostasis.
VONVENDI is a recombinant von Willebrand factor (VWF) that replaces deficient or dysfunctional VWF to restore platelet adhesion and hemostasis. Used for Von Willebrand disease (on-demand treatment and routine prophylaxis of bleeding episodes).
At a glance
| Generic name | VONVENDI |
|---|---|
| Also known as | vonicog alfa, TAK-577, rVWF |
| Sponsor | Takeda |
| Drug class | Recombinant von Willebrand factor |
| Target | von Willebrand factor (VWF) |
| Modality | Biologic |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Von Willebrand factor is a critical blood protein that mediates platelet adhesion to damaged blood vessel walls and serves as a carrier protein for factor VIII. VONVENDI is a recombinant human VWF produced in mammalian cells that restores hemostatic function in patients with von Willebrand disease by enabling proper platelet adhesion and improving factor VIII levels, thereby reducing bleeding episodes.
Approved indications
- Von Willebrand disease (on-demand treatment and routine prophylaxis of bleeding episodes)
Common side effects
- Thrombosis
- Headache
- Injection site reactions
- Dizziness
- Chest discomfort
Key clinical trials
- An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)
- A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD) (PHASE3)
- Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial (PHASE3)
- A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD) (PHASE3)
- Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD)
- A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD) (PHASE3)
- A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD) (PHASE3)
- Minimize Menorrhagia in Women With Von Willebrand Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VONVENDI CI brief — competitive landscape report
- VONVENDI updates RSS · CI watch RSS
- Takeda portfolio CI